Custom RNA Interference Service
News Apr 12, 2007
The cellular RNA interference (RNAi) pathway can be used to regulate gene expression for the purpose of understanding or discovering gene function. RNAi has found significant utility in the drug development pipeline. BIOO Scientific is launching a service to perform in vivo RNAi testing to facilitate progress in the drug pipeline (target identification, characterization and drug development).
The complete and integrated workflow includes the following:
I. Team of scientists with years of gene knockdown and drug study experience that will provide expert customer support and consulting relating to experimental design and analysis.
II. Service to identify siRNA that are specific and effective at reducing the target gene in cells derived from the target tissue.
III. Service for the delivery of RNAi molecules into animals.
IV. Service to analyze gene inhibition, distribution and toxicology in animal tissues (Pharmacodynamics and Pharmacogenomics).
V. Customized Report
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.